News & Publications

All 21 /Dissemination 4 /News 21 /Patients 3 /Prime-CKD 17 /Publications 8 /Stories 2

Reflecting on the highlights of ASN Kidney Week 2024

Now that everyone is back at base, it’s a perfect moment to look back on the highlights of ASN Kidney Week 2024. Various co-workers and partners of the PRIME-CKD consortium attended Kidney Week in beautiful, autumnal San Diego. They participated in poster presentations...

PRIME-CKD members Heerspink and Gorriz involved in promising SMART study

At the ASN conference, clinical pharmacologist Hiddo L. Heerspink of the University Medical Center Groningen presented remarkable findings from the SeMaglutide and Albuminuria Reduction Trial in Obese Individuals..

PRIME-CKD @ASN

Many of our consortium partners will be attending and participating in ASN this week. There will be several poster presentations by PhD students from UMCG, along with oral presentations by our partners. Notably, Hiddo Lambers Heerspink will be presenting....

Publication BePRECISE in Nature Magazine

An important publication in the field of precision medicine, to which PRIME-CKD PI Maria Gomez from Lund University contributed, has been published in Nature Medicine. The aim of this publication is to standardize the reporting of research...

Renalytix and Steno Diabetes Center Announce Precision Medicine Collaboration

The PRIME-CKD consortium partner Renalytix and the Steno Diabetes Center Copenhagen are pleased to announce a collaboration aimed at advancing precision medicine solutions for patients with Diabetes and Chronic Kidney Disease (DKD).

One year of PRIME-CKD: where are we now?

In April and May the consortium has had two important meetings: the annual consortium meeting and the annual stakeholder meeting. On April 25 and 26 over 40 consortium members met in beautiful Valencia (Spain) to meet each other..

CTIS application

In February, our Danish partners at the Steno Diabetes Center in Copenhagen completed the Clinical Trial Information System (CTIS) application at the European Medicine Agency in a joint effort with colleagues at the University Clinic Hamburg-Eppendorf...

EMA Qualification

In 2023 PRIME-CKD project leader Hiddo Lambers Heerspink and Lesley Inker (Tufts Medical Center, Boston), co-authored an important paper in Nature Medicine on the use of GFR slope as a surrogate endpoint for kidney failure...

PRIME-CKD explained by Hiddo Lambers Heerspink

It was a breakthrough in treatment for people with chronic kidney damage a few years ago. By chance it was discovered that kidney patients benefit significantly from medications that lower blood sugar levels, originally developed...

Outstanding publication of our partner Renalytix about kidneyintelX.dkd: a prognostic test for the assessment of diabetic kidney disease progression

The PRIME-CKD consortium is proud to share with you a new publication by our partner Renalytix. This study describes the development and validation of an updated version of KidneyIntelX (kidneyintelX.dkd) to stratify...

Inspiring publication of our partner University of Michigan about improving outcomes in patients with type 2 diabetes

The PRIME-CKD consortium is proud to share with you a new publication by our partner Michigan University. This study looks into the relationship between the sodium-glucose co-transporter 2 (SGLT2) inhibitor canagliflozin...

Kick-off stakeholder network PRIME-CKD!

On Friday 24th November 2023 a diverse group of stakeholders from all over the world got together online to hear more about the PRIME-CKD consortium. Both patients, researchers and clinicians, regulatory bodies...

Excellent publication of our partner CBG about how biomarkers shape the decision-making in personalized medicine

The PRIME-CKD consortium is proud to share with you our first publication by our partner CBG. This study looks closely at how biomarkers have been used in patient selection for clinical precision medicine trials developing...

Clinical Translational Sci – 2023

A new publication by the PRIME-CKD team on precision medicine in regulatory decision making has seen the light. The study provides an in-depth review of the inclusion of biomarkers in clinical development programs of approved medicines in Europe...

PRIME-CKD at ASN Kidney Week

At last week’s ASN Kidney week in Philadelphia, PRIME-CKD PI’s presented the progress in bringing precision medicine to kidney patients. Nephrologists and other clinicians had stimulating discussions with the PRIME-CKD team...

Join Renalytics at ASN Kidney Week

This week the Kidney Week, initiated by the American Society of Nephrology, takes place in Philadelphia, PA. Approximately 12,000 kidney professionals from across the globe will join at Kidney Week 2023. The world's premier nephrology...

FDA Grants Marketing Authorization of KidneyIntelX.dkd

Breaking news for the CKD community! The PRIME-CKD consortium is proud to have on board Renalytix as partner. The FDA has granted marketing authorization to Renalytix techonology KidneyIntelX.dkd. This is an innovative...

Cycling challenge to raise awareness for kidney diseases: 500 km in 24 hours

Saturday July 1st, 32 teams took on a great challenge: the Coast to Coast Challenge in The Netherlands. The teams had to cycle 500 km from Zoutkamp to Zoutelande in 24 hours. The start and finish where not chosen randomly...

Succesfull kick-off meeting Groningen

On April 13 and 14 2023 the PRIME-CKD consortium came together in Groningen for the kick-off meeting. Partners from the USA and multiple European countries came together to discuss the goal and the work packages of PRIME-CKD...

Prime-CKD International-attention for project start

International attention for project start

The PRIME-CKD project officially started on 1 January 2023. We are very motivated to disseminate our project and outcomes publicly and therefore we sent multiple press releases. They were published in national and international press...

The launch of PRIME-CKD

We are thrilled to announce the launch of our new research project, PRIME-CKD. We are committed to making significant strides in healthcare and improving the lives of individuals affected by chronic kidney disease...